STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3530 by analyst upside · 2026-08-13
LFST
LifeStance Health Group, Inc.
Healthcare · Market Cap $5B · P/E 87.4x
ANALYST PRICE TARGET
+5.5%
implied upside to consensus target
Current Price $12.23
Consensus Target $12.9
Bull Target $16.0
Bear Target $9.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
6
Hold
2
Sell
0
52-Week Low $4.77
52-Week High $12.43
YTD Return +75.7%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) 87.4x
Forward P/E 23.4x
EPS (TTM) $0.14
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1.6B
Profit Margin 3.2%
52-WEEK RANGE
52-Week Low $4.77
52-Week High $12.43
Current Price $12.23
Bear Target $9.0
Bull Target $16.0
● Now $12.23 ● Target $12.9
TRADING DATA
Avg Volume 3.7M
YTD Return +75.7%
Analyst Count 10
Consensus Buy
Upside to Target +5.5%
Last Updated 2026-08-13

ANALYST SUMMARY

LifeStance Health Group, Inc. (LFST) is currently trading at $12.23 with a Wall Street consensus price target of $12.9, implying potential upside of 5.5% over the next 12 months. 10 analysts currently cover LFST, with a consensus rating of Buy - 80% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $16.0, while the most cautious has a target of $9.0.

LFST operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 75.7% year-to-date and is currently trading near the upper end of its 52-week range of $4.77 – $12.43.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for LFST, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Goldman Sachs ● Initiated
Buy → Neutral 2026-06-05 Building track record
JP Morgan - Reiterated
Neutral → Neutral 2026-05-14 43% win rate (7 calls)
BTIG - Reiterated
Buy → Buy 2026-05-08 38% win rate (8 calls)
Barclays - Reiterated
Overweight → Overweight 2026-03-06 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-02-26 Building track record
UBS - Reiterated
Buy → Buy 2026-02-26 33% win rate (6 calls)
Keybanc - Reiterated
Overweight → Overweight 2026-02-26 Building track record
BTIG - Reiterated
Buy → Buy 2026-02-02 38% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
59
out of 100
Coverage depth
18/30
Consensus clarity
19/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →